News
New 23andMe Buyer Regeneron Promises to Prioritize Security
Regeneron Pharmaceuticals said in a press release yesterday that it would acquire 23andMe’s Personal Genome Service (PGS), Total Health and Research Services business lines, alongside its Biobank and associated assets, for $256m. Subject to bankruptcy court and regulatory approvals, the deal is expected to close in the third quarter.
Futurism on MSN3d
Bankrupt 23andMe Just Sold Off All Your DNA DataYour DNA results are in — and they're 100% the property of a pharmaceutical manufacturer. It was announced today that 23andMe ...
The DNA testing firm 23andMe says it has entered into an agreement to be acquired by Regeneron Pharmaceuticals for $256m ...
Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...
Pharmaceutical maker Regeneron announced Monday it will buy genetic testing company 23andMe for $256 million following a bankruptcy auction. Regeneron said it will acquire 23andMe's genomics ...
Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...
When Genetic Data Meets Law Enforcement. The 23andMe acquisition brings to mind another recent controversy involving genetic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback